Comparative Pharmacology
Head-to-head clinical analysis: CENTANY versus ELASE CHLOROMYCETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTANY versus ELASE CHLOROMYCETIN.
CENTANY vs ELASE-CHLOROMYCETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
Topical application: Apply thin layer to affected area 2-3 times daily.
None Documented
None Documented
8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure).
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%).
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Category C
Category C
Topical Antibiotic
Topical Antibiotic and Debriding Agent